Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Leases (2016 - 2018)

Sangamo Therapeutics (SGMO) has 3 years of Capital Leases data on record, last reported at $27.7 million in Q4 2018.

  • For Q4 2018, Capital Leases rose 11.93% year-over-year to $27.7 million; the TTM value through Dec 2018 reached $27.7 million, up 11.93%, while the annual FY2018 figure was $27.7 million, 11.93% up from the prior year.
  • Capital Leases reached $27.7 million in Q4 2018 per SGMO's latest filing, up from $26.9 million in the prior quarter.
  • Across five years, Capital Leases topped out at $27.7 million in Q4 2018 and bottomed at $213000.0 in Q1 2016.
  • Average Capital Leases over 3 years is $12.4 million, with a median of $3.9 million recorded in 2016.
  • Peak YoY movement for Capital Leases: soared 1744.13% in 2017, then rose 11.93% in 2018.
  • A 3-year view of Capital Leases shows it stood at $3.9 million in 2016, then surged by 527.07% to $24.7 million in 2017, then increased by 11.93% to $27.7 million in 2018.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $27.7 million in Q4 2018, $26.9 million in Q3 2018, and $26.2 million in Q2 2018.